Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention

Thrombosis and Haemostasis

Volumn 101, Issue 2, 2009, Pages 340-344

  Busch, Gabriele ^a   Steppich, Birgit ^a   Sibbing, Dirk ^a   Braun, Siegmund Lorenz ^a   Stein, Andreas ^a   Groha, Philipp ^a   Schömig, Albert ^a   Kastrati, Adnan ^a   Von Beckerath, Nicolas ^a   Ott, Ilka ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antithrombin; Leukocyte function activation; Platelet pharmacology

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD40 LIGAND; CYTOKINE; DUAL SPECIFICITY PHOSPHATASE 2; GLYCOPROTEIN IB ALPHA; HEPARIN; HIRULOG; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PADGEM PROTEIN; TUMOR NECROSIS FACTOR; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; HIRUDIN DERIVATIVE; LEUKOCYTE ANTIGEN; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DOUBLE BLIND PROCEDURE; FACIAL EXPRESSION; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKOCYTE ACTIVATION; MALE; MONOCYTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE; ANGIOCARDIOGRAPHY; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RADIOGRAPHY; THROMBOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTIGENS, CD; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MONOCYTES; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 62449174262     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-09-0582     Document Type: Article

References (14)

1. McNicol A, Israels SJ: Platelets and anti-platelet therapy, J Pharmacol Sci 2003; 93: 381-396.
2. Smith SC, Jr., FeldmanTE, Hirshfeld JW, Jr., et al.; ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166-286.
3. Lincoff AM, Kleiman NS, Kereiakes DJ, et al: Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. J Am Med Assoc 2004; 292: 696-703.
4. Lincoff AM, Bittl JA, Harrington RA, et al: Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/ IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. J Am Med Assoc 2003; 289: 853-863.
5. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-256.
6. Aggarwal A, Sobel BE, Schneider DJ. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention J Thromb Thrombolysis 2002; 13: 161-165.
7. Keating FK, Dauerman HL, Whitaker DA, et al: The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis 2005; 16: 401-405.
8. Chen MS, Lincoff AM. Direct thrombin inhibitors. Curr Cardiol Rep 2005; 7: 255-259.
9. Busch G, Seitz I, Steppich B, et al. Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes: implications in acute myocardial infarction. Arterioscler Thromb Vasc Biol 2005; 25: 461-466.
10. Di Cera E: Thrombin interactions. Chest 2003; 124: 11S-17S.
11. Sibbing D, Busch G, Braun S, et al: Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J 2008; 29: 1504-1509.
12. Anand SX, Kim MC, Kamran M, et al: Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 2007; 100:417-424.
13. Ott I, Neumann FJ, Gawaz M, et al: Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996; 94: 1239-1246.
14. Kastrati A, Neumann FJ, Mehilli J, et al: Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359: 688-696.